So here’s the lowdown: Clarity Pharmaceuticals is touting its Cu-64 SAR-bisPSMA as a heavy hitter in prostate cancer detection. The just-released results from their Co-PSMA trial show this product more than doubles lesion detection compared to Ga-68 PSMA-11. If you think that’s just marketing fluff, hang tight—let’s slice through the stats.
The Co-PSMA trial was spearheaded by Prof Louise Emmett down at St Vincent's Hospital Sydney, and it aimed squarely at comparing two imaging products on patients with biochemical recurrence of prostate cancer. You’ve got your standard-of-care (SOC) Ga-68 PSMA-11 versus Clarity's new kid on the block, the Cu-64 SAR-bisPSMA. They rolled up their sleeves with a straightforward test on 50 guys who had surgery but were still dealing with rising PSA levels—a real hotbed for cancer recurrence.
Now, what do the numbers tell us? The study revealed that 64Cu-SAR-bisPSMA identified an average of 1.26 lesions per patient versus a measly 0.48 for Ga-68 PSMA-11—yeah, we're talking almost tripling effectiveness. That ratio isn’t just pretty; it’s backed by strong statistical significance (p
